Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ARVN | US
0.26
1.05%
Healthcare
Biotechnology
30/06/2024
04/10/2024
24.96
24.71
25.16
24.57
Arvinas Inc. a clinical-stage biotechnology company engages in the discovery development and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766 investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer which are in Phase 1/2 clinical trials; and ARV-471 an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc. Genentech Inc. F. Hoffman-La Roche Ltd. and Bayer AG. Arvinas Inc. was founded in 2013 and is based in New Haven Connecticut.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
43.3%1 month
36.0%3 months
53.4%6 months
53.4%-
17.70
2.83
0.00
0.00
-1.62
5.06
-
-366.20M
1.71B
1.71B
-
-63.40
-
40.40
-60.80
25.61
18.92
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
2.18
Range1M
2.79
Range3M
11.02
Rel. volume
0.96
Price X volume
11.22M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Mirum Pharmaceuticals Inc | MIRM | Biotechnology | 39.26 | 1.87B | -5.37% | n/a | 138.24% |
Intellia Therapeutics Inc | NTLA | Biotechnology | 17.99 | 1.83B | -3.02% | n/a | 10.95% |
VIRIDIAN THERAPEUTICS ORS INC | VRDN | Biotechnology | 23.92 | 1.83B | -1.36% | n/a | 3.96% |
MannKind Corporation | MNKD | Biotechnology | 6.49 | 1.78B | 3.18% | 124.00 | -149.80% |
Certara Inc. | CERT | Biotechnology | 11.09 | 1.78B | -2.46% | n/a | 29.96% |
Kiniksa Pharmaceuticals Ltd | KNSA | Biotechnology | 24.48 | 1.74B | -0.20% | n/a | 2.62% |
Recursion Pharmaceuticals Inc. Class A Common Stock | RXRX | Biotechnology | 6.11 | 1.72B | 0.00% | n/a | 15.38% |
PROK | PROK | Biotechnology | 1.695 | 1.65B | 3.04% | n/a | -0.69% |
NewAmsterdam Pharma Company N.V. Ordinary Shares | NAMS | Biotechnology | 18.22 | 1.64B | 4.53% | n/a | 0.15% |
Bicycle Therapeutics Limited | BCYC | Biotechnology | 23.6 | 1.63B | 4.61% | n/a | 4.89% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.62 | 0.76 | Cheaper |
Ent. to Revenue | 5.06 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 2.83 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 53.38 | 74.67 | Lower Risk |
Debt to Equity | 0.00 | -1.82 | Expensive |
Debt to Assets | 0.00 | 0.26 | Cheaper |
Market Cap | 1.71B | 3.73B | Emerging |